Literature DB >> 10907909

Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women.

J G Feldman1, H Minkoff, S Landesman, J Dehovitz.   

Abstract

BACKGROUND: To clarify the role of heterosexual transmission of hepatitis C virus (HCV) and to identify associated risk factors. GOAL: To compare risk factors with infection among women with HCV, HIV-1, and hepatitis B virus (HBV). STUDY
DESIGN: A cross-sectional study of the prevalence of HCV, HIV-1, and HBV in a sample of 599 sexually active, nontransfused, inner-city women with no evidence of intravenous drug use.
RESULTS: The prevalence of HCV was 1.6%, compared with 2.0% for HIV-1 and 18.8% for HBV; 75% of women infected with HCV were also infected with HIV-1 or HBV (P < 0.001). Women engaging in very high-risk sexual behavior were 14.2 times more likely to have HCV than other women (95% CI, 1.8-642.5).
CONCLUSIONS: The epidemic of HCV may be facilitated by high-risk sexual behavior. The relatively high prevalence of HCV suggests the need for more widespread screening among inner-city females.

Entities:  

Mesh:

Year:  2000        PMID: 10907909     DOI: 10.1097/00007435-200007000-00007

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  24 in total

Review 1.  Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.

Authors:  Susanna Naggie; Mark S Sulkowski
Journal:  Gastroenterology       Date:  2012-05       Impact factor: 22.682

Review 2.  Non-injection drug use and Hepatitis C Virus: a systematic review.

Authors:  Roberta Scheinmann; Holly Hagan; Corina Lelutiu-Weinberger; Rebecca Stern; Don C Des Jarlais; Peter L Flom; Shiela Strauss
Journal:  Drug Alcohol Depend       Date:  2006-12-15       Impact factor: 4.492

3.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

4.  Presence of hepatitis C virus (HCV) RNA in the genital tracts of HCV/HIV-1-coinfected women.

Authors:  Marek J Nowicki; Tomasz Laskus; Georgia Nikolopoulou; Marek Radkowski; Jeffrey Wilkinson; Wenbo B Du; Jorge Rakela; Andrea Kovacs
Journal:  J Infect Dis       Date:  2005-09-29       Impact factor: 5.226

5.  Molecular evidence of male-to-female sexual transmission of hepatitis C virus after vaginal and anal intercourse.

Authors:  P Halfon; H Riflet; C Renou; Y Quentin; P Cacoub
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

6.  Rapid screening for co-infection of HIV and HCV in pregnant women in Benin City, Edo State, Nigeria.

Authors:  M U Duru; H S A Aluyi; K C Anukam
Journal:  Afr Health Sci       Date:  2009-09       Impact factor: 0.927

Review 7.  Screening in liver disease.

Authors:  Paolo Del Poggio; Marzio Mazzoleni
Journal:  World J Gastroenterol       Date:  2006-09-07       Impact factor: 5.742

8.  Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection.

Authors:  J Ghosn; C Deveau; C Goujard; I Garrigue; N Saïchi; J Galimand; Z Nagy; C Rouzioux; L Meyer; M-L Chaix
Journal:  Sex Transm Infect       Date:  2006-08-21       Impact factor: 3.519

9.  Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS).

Authors:  Toni Frederick; Pamela Burian; Norah Terrault; Mardge Cohen; Michael Augenbraun; Mary Young; Eric Seaberg; Jessica Justman; Alexandra M Levine; Wendy J Mack; Andrea Kovacs
Journal:  AIDS Patient Care STDS       Date:  2009-11       Impact factor: 5.078

Review 10.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.